Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
These results indicate that synthetic REV-ERB ligands that pharmacologically target the circadian rhythm may be beneficial in the treatment of sleep disorders as well as metabolic diseases
2007 Nov 15
Formula: C22H24ClN3O4
76(11):3340-50
Retigabine dihydrochloride Catalog No.:M9949-10 These results indicate that syntheticEzogabine, also known as Retigabine, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. Ezogabine works primarily as a potassium channel openerthat is, by activating a certain family of voltage gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and may hold promise
US$ 50.00
US$ 13.98
US$ 13.98
US$ 35.98
US$ 40.00
US$ 17.98
US$ 13.98
US$ 19.98
US$ 50.00
US$ 20.00